Alembic Pharmaceuticals Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,150Cr
- +25.7% YoY
- +16.3% QoQ
- Net profit
- ₹172Cr
- +11.7% YoY
- −14.9% QoQ
- Margin
- 15%
- −1 pp YoY
- +3 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance (Page 4). FY27 EBITDA margins expected to be in high teens, factoring operating leverage in core business partially offset by US branded business margin dilution (~150 bps).
From Alembic Pharmaceuticals Ltd's Q1 FY27 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance (Page 4).
- US branded specialty business projected to scale up over next few quarters and start contributing positively to profit from FY28 onwards (Pages 6,14).
- Around 15 new product launches planned in the US in next 9 months, with a similar number expected next year, supporting sustained US growth (Page 13).
- ROW (Rest of World) markets expected to achieve around 15% growth in INR terms in FY27, with potential to surpass this depending on market conditions (Page 14).
2 more points from Alembic Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Alembic Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Alembic Pharmaceuticals incurred about INR400 crores of capex in the last year, contributing to higher depreciation/amortization.
- Preventive debottlenecking and maintenance upgrades were done in facilities (e.g., Ophthaline) to expand capacity without incremental capex.
- Strategic investments ongoing in R&D, manufacturing capabilities, and US branded business platform.
- Investments in US branded platform focus on building commercial capabilities and scaling specialty franchises; primarily marketing and field force costs with no manufacturing asset investments.
- Working on peptide development, regulatory filings, and portfolio development initiatives as part of R&D capital.
2 more points from Alembic Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Alembic Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Alembic Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.
Alembic Pharmaceuticals Ltd — Quarterly revenue & net profit
Alembic Pharmaceuticals Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,150 | 1,711 | +25.7% | 1,848 | +16.3% |
| Operating profit (EBITDA) | 332 | 281 | +18.1% | 228 | +45.6% |
| Operating margin | 15% | 16% | -1 pp | 12% | +3 pp |
| Profit before tax | 222 | 190 | +16.8% | 119 | +86.6% |
| Net profit (PAT) | 172 | 154 | +11.7% | 202 | -14.9% |
| EPS (₹) | 8.80 | 7.85 | +12.1% | 10.31 | -14.6% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.6K Cr, net profit ₹334 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Alembic Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Alembic Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Alembic Pharmaceuticals Ltd Q1 FY27 results?
US generics business expected to grow mid to high teens in FY27, upgraded from low to mid-teens earlier guidance (Page 4). FY27 EBITDA margins expected to be in high teens, factoring operating leverage in core business partially offset by US branded business margin dilution (~150 bps).
What is Alembic Pharmaceuticals Ltd share price analysis?
Alembic Pharmaceuticals Ltd currently shows a below-average growth signal. The stock trades at a P/E of 22.3 with a market cap of ₹16,624 Cr. Investors should review the full earnings analysis for detailed insights.
Is Alembic Pharmaceuticals Ltd planning capital expenditure?
Alembic Pharmaceuticals incurred about INR400 crores of capex in the last year, contributing to higher depreciation/amortization.
Keep Alembic Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
